Skyepharma Plans Joint Development With Novartis

SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]

Skyepharma Begins Requip Ocr Clinical

Skyepharma has initiated Phase III clinical trials of the oral controlled release formulation of GlaxoSmithKline‘s Requip (Ropinirole HCl). The new once daily formulation for Parkinson’s disease has been developed utilizing SkyePharma’s Geomatrix technology. Requip OCR is expected to simplify the treatment regime for patients using this drug, thus improving patient convenience and compliance. The company Read more about Skyepharma Begins Requip Ocr Clinical[…]

Approvable Letter Received For Uroxatral

SkyePharma PLC and Sanofi-Synthelabo have received an “approvable letter” from the US FDA for UroXatral (once-daily formulation of alfuzosin) for the symptomatic treatment of benign prostatic hyperplasia. The formulation utilizes SkyePharma’s proprietary oral drug delivery technology, GEOMATRIX. The New Drug Application for UroXatral was submitted in December 2000 in the United States. Michael Ashton, SkyePharma’s Read more about Approvable Letter Received For Uroxatral[…]

Skyepharma Licenses Dermatology Technology

SkyePharma PLC has licensed rights to three topical drug delivery technologies, Crystalip, DermaStick and the ES-Gel system, from Bioglan Pharma PLC. Under the terms of the agreement SkyePharma has paid $9 million in cash and will obtain certain exclusive development and commercial rights in relation to new products from the Crystalip and DermaStick technologies and Read more about Skyepharma Licenses Dermatology Technology[…]